The observed clinical activity signals of the combination therapy comprising Cobolimab, an anti-TIM-3 monoclonal antibody, and Dostarlimab (Jemperli), an anti-PD-1 antibody, in heavily pretreated patients with advanced/metastatic non-small cell lung cancer (NSCLC) are highly promising. This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.